Agendia Announces Level 1 Inclusion of MammaPrint(R) Breast Cancer Test in Updated National Comprehensive Cancer Network(R) (NCCN) Guidelines

The NCCN recommends Agendia's MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3) MammaPrint is now the only ... Diagnostics, Oncology, Personalized Medicine Agendia, MammaPrint, Breast Cancer Test, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news